We are CSL Seqirus. One of the world's largest influenza vaccine manufacturers and the only company fully dedicated to flu prevention. With over a century's worth of innovations, CSL Seqirus provides the experience needed to help fight flu with flu360.
FLUCELVAX® is the first and only FDA-approved cell-based seasonal influenza vaccine in the US. Visit flu360.com to learn more.
flu360 offers clinical, financial, and operational solutions for your flu vaccination business year-round. Learn more and partner with CSL Seqirus at flu360.com.
UIVI launched late last year with the goal to accelerate universal flu vaccine development, specifically by looking at how the immune system develops responses against multiple strains. The group brings together industry, academia, nonprofits and government. This year, UIVI says it will "undertake t...
flu360 offers clinical, financial, and operational solutions for your flu vaccination business year-round. Learn more and partner with CSL Seqirus at flu360.com.
Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older. ...
AFLURIA® is a seasonal flu vaccine approved for ages 6 months and older and is for a wide range of patients. Learn more at flu360.com.
FLUAD® with MF59® Adjuvant is a flu vaccine designed to strengthen, broaden, and lengthen the duration of the immune response and is approved for patients 65+. Visit flu360.com to learn more.
AFLURIA® is a seasonal flu vaccine approved for ages 6 months and older and is for a wide range of patients. Learn more at flu360.com.
Pandemic influenzais a contagious, airborne respiratory disease that affects all age groups, associated with higher morbidity and mortality compared to seasonal flu. Audenz is the first adjuvanted, cell-based influenza vaccine targeting protection from H5N1, meant for quick deployment in the US and ca...